Aurobindo Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹10,263 crore and net profit of ₹1,124 crore for the September 2026 quarter.
Aurobindo Pharma (NSE: AUROPHARMA) closed at ₹1,799.00 on 20 Nov 2026, up 49.0% over the past year. Its market capitalisation is ₹1,03,510 crore and it trades at 25.5 times earnings.
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.